A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-07-26
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 55); relationship: not assessed
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-30 (study day 111); relationship: not assessed
severe
assessed
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 120); relationship: Y
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-12-15 (study day 126); relationship: not assessed
Data queries
No data queries.